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The American Red Cross (ARC), Penn-Jersey
Region, Cooperative Sickle Cell Donor Program
(CSCDP) began in September 1997 at the request of
one of the clinical hematologists treating patients with
sickle cell disease (SCD) at the Children’s Hospital of
Philadelphia (CHOP). The ARC Penn-Jersey Region
now collects more than 1000 productive units of blood
per month from donors who voluntarily participate in
this program designed to attract African American
blood donors. This program is successful because of
the combined efforts of CHOP physicians, the ARC
Penn-Jersey Region, the Philadelphia/Delaware Valley
Chapter of the Sickle Cell Disease Association of
America, and generous blood donors. The program
currently serves two children’s hospitals in
Philadelphia. The keystone of the program is the blue
tie tag that was developed by CHOP and ARC Penn-
Jersey Region staff used to identify units in the
program.
Over 1000 children with SCD are enrolled in the
comprehensive sickle cell center (CSCC) at CHOP
where they receive medical care during routine and
acute illness visits. Approximately 115 children receive
chronic transfusion therapy and have ongoing needs
for “blue tag” units from the CSCDP. Primary and
secondary stroke prevention is the most common
indication for transfusion, followed by prevention of
acute chest syndrome and acute splenic sequestration
recurrences. Many children receive acute RBC
transfusions to decrease the morbidity of SCD
complications, such as acute chest syndrome and acute
exacerbation of anemia, or as preoperative therapy to
decrease the risk of acute chest syndrome following
general anesthesia.
Transfusion Protocol
The CHOP protocol for transfusion of RBCs for
patients with SCD consists of prospective phenotype
matching for C, E, and K, and issuance of prestorage
leukocyte-reduced “CMV safe,” irradiated RBCs that are
HbS negative. The HbS testing is done at CHOP using a
rapid solubility test. In the event that a blue tag unit is
HbS positive, it is transferred to another institution for
use in their general inventory.
The practice of matching for C, E, and K, when
phenotype-matched donor RBCs are needed for
patients with SCD, is consistent with other hospitals’
practices.1 At CHOP, to determine the need for
matching, each patient with SCD has an extended RBC
phenotype performed using an untransfused speci-
men. If the patient has been recently transfused, other
methods may be needed to determine the phenotype
of the patient’s RBCs. While a hypotonic wash method
can be used to isolate HbS-positive RBCs (the patient’s
RBCs), molecular methods are useful for the detection
and identification of variants of e and D that occur at a
high rate in this population. In the event the antigen
profile is unknown, RBCs are released that are negative
for C, E, and K until a true phenotype can be
determined.
For patients on chronic transfusion programs,many
of whom are patients with SCD, our protocol calls for
transfusing RBCs less than 21 days old at the time of
transfusion. The rationale for this practice is that the in
vivo recovery and survival of transfused RBCs decline
with storage age and chronically transfused patients
will have higher Hb values, longer transfusion intervals,
and ultimately less transfusion iron loading, if fresher
RBCs are used. It is not always possible to meet this
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requirement if there are other constraints such as
multiple antibodies or limited supplies. In addition,
this freshness protocol is not applied to patients with
SCD that have acute or one-time indications for
transfusion.
Our SCD transfusion protocols support a very large
RBC exchange program. We currently treat more than
50 patients who return to the apheresis unit for partial
or complete RBC exchange every 3 to 4 weeks. Many
of these patients are on prophylactic protocols for
primary or secondary stroke prevention and require
the percentage of HbS to be maintained at either less
than 30 percent or less than 50 percent (for secondary
stroke prevention in selected patients).2 Patients
receiving RBC exchange usually have peripheral
access. In the event that peripheral access fails, a port
that is suitable for use in apheresis is placed for access.
Automated RBC exchange transfusion is preferred at
our institution for patients with SCD requiring chronic
transfusions to decrease total body iron burden,
thereby preventing or forestalling iron overload.3
Selection of Protocol
Eighteen to 25 percent of all patients with SCD are
alloimmunized because of RBC antigen frequency
disparities between African American patients with
SCD and European American blood donors. Because of
the high frequency of alloimmunization in this patient
population, all children with SCD have an extended
RBC antigen phenotype performed in their first year of
life, before their first RBC transfusion or at entry into
the CHOP CSCC.With approximately two-thirds of the
antibodies formed having specificities for antigens in
the Rh or Kell systems, we adopted the practice of
transfusing RBCs that are C, E, and K-matched. Multi-
institutional studies conducted to determine whether
RBC transfusions could decrease or prevent
neurological and respiratory complications in patients
with SCD have also adopted transfusion guidelines
using C,E,and K-matched RBCs. The frequency of RBC
alloimmunization in these studies was apparently
reduced to a rate of 1 to 8 percent using phenotype-
matched RBCs.4,5 Those antibodies that did develop
had specificities in the Duffy, Kidd, and MNS systems.
Presently,we are analyzing the number of patients with
SCD and alloimmunization and the number of delayed
hemolytic transfusion reactions since the CSCDP began
in 1997.
Summary of Data from the Program
To provide an overview of this program, we
reviewed the transfusion experiences of patients with
SCD at our institution from 2002 to 2005. On the
average, more than 3800 RBCs with blue tags were
received per year,or 73 units per week. This represents
36 percent of all the RBCs received over this time
period. These RBCs provided more than 16,000
transfusions over the 4-year period,about 58 percent of
the total RBC transfusions. Of the blue tag units
received, 92 to 93 percent were transfused.
Interestingly, only 51 percent of these were transfused
to patients with SCD; the remaining units were
transferred into the general inventory and transfused to
patients with other diagnoses. At CHOP, blue tag units
are also routinely ordered and used for patients with
thalassemia.
The range of transfusion exposures among the
patients with SCD in this 4-year period was broad, with
66 percent of these patients receiving no transfusions,
19 percent receiving 1 to 9 transfusions, 9 percent
receiving 10 to 99 transfusions, and 5.5 percent
receiving more than 99 transfusions. About 70 percent
of the transfusions, blue tag or general inventory, went
to this latter group of very heavily transfused patients.
These figures do not represent these patients’ total
lifelong transfusion history, only the experience of the
4 years reviewed.
Overall, only about 60 percent of RBCs transfused
to patients with SCD came from the blue tag inventory,
the remainder came from general inventory. Viewed
from the patient’s perspective, 137 of the 300 patients
with SCD who were transfused in the 4 years reviewed,
or 46 percent, received 90 percent or more of their
units from the blue tag inventory; 93 patients or 31
percent received all of their transfusions from the blue
tag inventory. No one patient of these 93 who were
entirely supported with the blue tag inventory
received more than 50 transfusions total and only 7
received more than 10. On the other extreme, there
were 47 patients, or 16 percent of those transfused,
who received 0 to 10 percent of their transfusions from
the blue tag inventory,37 of them receiving no blue tag
units at all. This group of patients, who received no
blue tag units over 4 years, included 3 patients who
received a total of more than 100 units.
We also investigated 14 patients with SCD who,
although they received more than 10 RBC transfusions,
less than 10 percent of their blood support was
provided with blue tag units. In nine of these cases,
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additional antibodies including anti-S, -Jka, -Jkb, -Jsa, -V, -f,
-Cob, and -Wra made it difficult to provide the patient’s
RBC needs from within the blue tag inventory. In two
cases, the patient’s RBCs were group B, D–; in two
cases, R2R2 RBCs were needed because of auto-anti-e,
and in one case, extended phenotype matching had
been prescribed because of unexplained hemolytic
transfusion reactions. It is possible that the diagnosis of
SCD was not known to the blood bank in one case.
Donor Recruitment Process
There are more than 10,000 donors who have self-
identified for the CSCDP. Demographic analysis of the
program reveals a younger age group than the general
donor population at the ARC in Philadelphia with the
majority of donors between 19 and 29 years of age. In
addition, because of the distribution of ABO groups,
one-half of the donated RBCs are group O. When a
donor walks into any collection site in the Penn-Jersey
Region, there is a poster display showing a bright
young child with SCD and the distinctive blue tie tags.
The names and logos for CHOP and the ARC are
displayed on the front of the tag as co-branding for the
CSCDP. The back of the tie tag has information about
SCD and the need for African American donors. A
donor who decides to be an “African American Hero”
takes a tie tag and hands it to the phlebotomist. Once
the donor meets all of the usual donor criteria, the
collection staff attaches the blue tie tag to the primary
collection bag. The tie tag remains with the unit while
other components are made from the donation. Plasma
and platelets are not labeled with a tie tag. The tie tag
is the marker to ensure that each RBC is captured as a
CSCDP unit. The RBCs are placed in storage locations
according to the C, E, and K phenotype of the
component, thus making the units easily accessible
when the order for transfusion is being completed.
Since the donors are very likely to be African
Americans, extended typing for antigens in the Kidd,
Duffy, and MNS systems are not performed, as the
population frequencies of these antigens are similar in
the donors and patients. However, segments are
retained for testing for rare blood types. African
Americans are the population of interest for antigens
such as hrB, U, Jsb, and Hy, as this population has the
highest chance (albeit low) to be negative for these
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antigens. If a rare blood type is found, the unit is
selected for long-term storage in the frozen state and
the donor is invited to be listed in the American Rare
Donor Program.
Communication Process Between the
Transfusion Service and Blood Supplier
Our transfusion protocol for patients with SCD
requires some effort on the part of the blood bank
technologist. Ideally, for each patient’s blood order,
units must be obtained from the blue tag inventory that
are leukocyte-reduced, irradiated, less than 21 days old,
ABO and D type-specific, crossmatch compatible,
phenotype matched for C, E, and K, as well as antigen
negative for other clinically significant antibodies
present in the patient’s plasma. This protocol is the
same for all patients with SCD, whether they are
inpatients or outpatients, scheduled or emergent,
except that the freshness criterion is not applied for
acute transfusions. The expectation for outpatient
transfusions, which comprise the majority of these
transfusions, is that patients will have their blood bank
specimens drawn 1 to 3 days before the transfusion so
as not to wait for blood availability when they arrive for
the transfusions.
To meet these demands, there must be good
coordination between the clinical service, the blood
bank, the blood supplier, and the regional and national
reference laboratories. Each week, the schedule of
outpatient transfusions for the following week is
compiled for both simple transfusions and RBC
exchanges and is transmitted by fax to the blood bank.
This schedule shows the anticipated date of transfusion
and the anticipated number of units or volume of RBCs
needed. A blood bank technologist reviews this
schedule with the patient’s ABO blood group, D type,
C, E, and K phenotype, and antibody history, and then
places a blood order with the ARC for each patient’s
needs, typically two days after the initial fax. The
technologist will sometimes order 1 or 2 additional
units if the patient has a history of clinically
insignificant antibodies that interfere with cross-
matching. In addition, the technologist will review the
existing inventory of blue tag units and will order
additional units to accommodate unscheduled blood
orders for patients with SCD. This inventory of extra
units typically consists of 5 group A and 5 group O, all
negative for C, E, and K; this selection maximizes
flexibility in using them for unscheduled needs. Finally,
the technologist identifies blue tag units that are older
than 21 days of storage, removes the blue tag, and
transfers them to the general RBC inventory.
The ARC IRL must then find units to fill these
orders, using units that will be less than 21 days old on
the date of transfusion and selected from the blue tag
inventory, if possible. Since the CSCDP provides a
generous supply of RBCs from a predominantly African
American background, the IRL is typically able to fill
the majority of orders, amounting to 60 to 80 units
each week,within 1 to 2 days. Orders for patients with
complex antibody problems may take several more
days. When the appropriate units are identified, they
are shipped to the hospital blood bank where these
units are stored separately from the rest of the available
inventory.
Unique Features of the Program
Although this program is very successful in
supporting our patients with SCD, there are some
challenges when the patient does not exhibit one of
the most common African American blood types. For
example, for a patient who is e–, and develops an 
anti-e or autoanti-e, there may be difficulty in locating
an e– blue tag RBC unit each time a transfusion is
needed. Similarly, patients who form other antibodies,
such as anti-S or -Jka, or -Jkb, may not be able to be
supported with blue tag units. If blood cannot be
found in the blue tag inventory, the decision whether
to delay transfusion or go outside the program must be
made.
Blue tag units in our CSCDP are available for use for
patients with elective and acute needs for blood
transfusions to reduce the morbidity and mortality
associated with SCD-related complications. Other
programs that use directed or selected donations
cannot often provide RBCs to patients with acute,
nonelective needs for RBC transfusions. Our program
continues to provide phenotype-matched RBCs for all
patients with SCD and, when possible, attempts to
transfuse patients using RBCs exclusively from this
unique donor program.
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